BACKGROUND: No standard chemotherapy regimen has been established for unresectable or recurrent small bowel adenocarcinoma (SBA). METHODS: Clinical courses of 132 patients with unresectable or recurrent SBA who received chemotherapy at 41 institutions in Japan were reviewed retrospectively. Patients were classified into five groups according to first-line chemotherapy regimens: fluoropyrimidine monotherapy (group A), fluoropyrimidine-cisplatin (group B), fluoropyrimidine-oxaliplatin (group C), fluoropyrimidine-irinotecan (group D), and other regimens (group E). RESULTS: The number of patients in each group was as follows: groups A, 60 patients; group B, 17 patients; group C, 22 patients; group D, 11 patients; and group E, 22 patients. Median progression-free survival (PFS) times were as follows: group A, 5.4 months; group B, 3.8 months; group C, 8.2 months; group D, 5.6 months; and group E, 3.4 months. Median overall survival (OS) times were as follows: group A, 13.9 months; group B, 12.6 months; group C, 22.2 months; group D, 9.4 months; and group D, 8.1 months. Patients in group C achieved significantly longer PFS times and substantially (but not significantly) longer OS times than patients in group A. After adjusting for clinical background characteristics, fluoropyrimidine-oxaliplatin therapy was a significant positive prognostic factor for PFS and OS times. CONCLUSION: The results suggest that fluoropyrimidine-oxaliplatin combination therapy is the most promising first-line chemotherapy regimen for unresectable or recurrent SBA.
BACKGROUND: No standard chemotherapy regimen has been established for unresectable or recurrent small bowel adenocarcinoma (SBA). METHODS: Clinical courses of 132 patients with unresectable or recurrent SBA who received chemotherapy at 41 institutions in Japan were reviewed retrospectively. Patients were classified into five groups according to first-line chemotherapy regimens: fluoropyrimidine monotherapy (group A), fluoropyrimidine-cisplatin (group B), fluoropyrimidine-oxaliplatin (group C), fluoropyrimidine-irinotecan (group D), and other regimens (group E). RESULTS: The number of patients in each group was as follows: groups A, 60 patients; group B, 17 patients; group C, 22 patients; group D, 11 patients; and group E, 22 patients. Median progression-free survival (PFS) times were as follows: group A, 5.4 months; group B, 3.8 months; group C, 8.2 months; group D, 5.6 months; and group E, 3.4 months. Median overall survival (OS) times were as follows: group A, 13.9 months; group B, 12.6 months; group C, 22.2 months; group D, 9.4 months; and group D, 8.1 months. Patients in group C achieved significantly longer PFS times and substantially (but not significantly) longer OS times than patients in group A. After adjusting for clinical background characteristics, fluoropyrimidine-oxaliplatin therapy was a significant positive prognostic factor for PFS and OS times. CONCLUSION: The results suggest that fluoropyrimidine-oxaliplatin combination therapy is the most promising first-line chemotherapy regimen for unresectable or recurrent SBA.
Authors: J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier Journal: Lancet Date: 2000-03-25 Impact factor: 79.321
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: J C Haan; T E Buffart; P P Eijk; M A van de Wiel; W N van Wieringen; P D Howdle; C J J Mulder; C J van de Velde; P Quirke; I D Nagtegaal; N C T van Grieken; H Grabsch; G A Meijer; B Ylstra Journal: Ann Oncol Date: 2011-05-17 Impact factor: 32.976
Authors: Matthew P Goetz; Charles Erlichman; Anthony J Windebank; Joel M Reid; Jeffrey A Sloan; Pamela Atherton; Alex A Adjei; Joseph Rubin; Henry Pitot; Evanthia Galanis; Matthew M Ames; Richard M Goldberg Journal: J Clin Oncol Date: 2003-09-08 Impact factor: 44.544
Authors: Alexander Wilhelm; Sascha A Müller; Thomas Steffen; Bruno M Schmied; Ulrich Beutner; Rene Warschkow Journal: J Gastrointest Surg Date: 2016-02 Impact factor: 3.452
Authors: Laura M Legué; Nienke Bernards; Valery Epp Lemmens; Ignace Hjt de Hingh; Geert-Jan Creemers; Felice N van Erning Journal: United European Gastroenterol J Date: 2019-06-14 Impact factor: 4.623